Research Corporation Technologies (RCT) of Tucson, Ariz.,announced last week that it has granted AmpliMed Corp., alsoof Tucson, an exclusive license to develop a family of chemicalcompounds called azonafides as treatments for breast, ovarian,colon, prostate, lung and other cancers.

The azonafides are anthracene analogs of the anti-cancer agentamonafide, which has been shown to bind to DNA and thusinhibit the topoisomerases necessary for cellular replication.Researchers have shown that although tumors eventuallybecome resistant to the parent drug, they remain susceptible toazonifide.

(c) 1997 American Health Consultants. All rights reserved.